All In Biotech

Drug Trial Radar · NCT07064525

Evaluate the Efficacy and Safety of SPC1001 Low in Patients With Essential Hypertension

A Multi-center, Randomized, Double-blind, Parallel, Phase 2b Study to Evaluate the Efficacy and Safety of SPC1001 Low in Patients With Essential Hypertension

Last checked: Nov 19, 2026Latest source record: Jul 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitationPivotal-lookingRandomized with 252 participants. This is a heuristic, not a regulatory label.

Status

Enrolling by invitation

Enrollment

252

Planned (sponsor's estimate)

Start

Dec 5, 2024

Primary completion

Dec 15, 2025

Study completion Feb 28, 2026

Sponsor

Sponsor type
Industry
First posted
Jul 14, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

\- Objective: This study aims to evaluate the safety and efficacy of the fixed-dose triple combination therapy (SPC1001 Low) of candesartan, amlodipine, and indapamide in adult patients with essential hypertension compared to dual-component therapies of each ingredient for 8 weeks. Additionally, it seeks to confirm the contribution of each component at low doses. \- Inclusion Criteria: Men and women aged 19 to 75 years whose blood pressure measured at the screening visit meets the following criteria. \- Exclusion Criteria: Patients whose blood pressure measured at the screening and randomization visits meets the criteria of MSSBP ≥180 mmHg or MSDBP ≥110 mmHg, among other conditions. \- Methods: This study is a multicenter, randomized, double-blind, parallel-group, phase 2b clinical trial to evaluate the safety and efficacy of the investigational drug after 8 weeks of administration. Screening assessments will be conducted within 4 weeks prior to randomization, and patients who meet the inclusion and exclusion criteria at the screening visit will be enrolled in the study after providing informed consent. These participants will undergo a 2-week run-in period during which they will take a placebo and participate in a lifestyle modification program.

Conditions

  • Hypertension (HTN)
  • NYHA Class III Heart Failure
  • NYHA Class IV Heart Failure
  • Diabete Mellitus

Interventions

  • SPC1001 LowDrug

    low-dose combination therapy

  • SPC5002Drug

    low-dose combination therapy

  • SPC5003Drug

    low-dose combination therapy

  • SPC5004Drug

    low-dose combination therapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The primary endpoint was determined by evaluating how mean sitting systolic blood pressure varied between the baseline measurement and week 8Time frame: change in MSSBP from baseline at week 8

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • CHA Gangnam Medical Center, CHA University

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.